与2019冠状病毒病疫苗相关的史蒂文斯-约翰逊综合征

IF 1.6 Q3 ALLERGY
Asia Pacific Allergy Pub Date : 2022-07-22 eCollection Date: 2022-07-01 DOI:10.5415/apallergy.2022.12.e30
João Marcelino, João Vieira, Fátima Ferreira, Irina Didenko, Rute Reis, Rita Silva, Regina Viseu, Elza Tomaz
{"title":"与2019冠状病毒病疫苗相关的史蒂文斯-约翰逊综合征","authors":"João Marcelino,&nbsp;João Vieira,&nbsp;Fátima Ferreira,&nbsp;Irina Didenko,&nbsp;Rute Reis,&nbsp;Rita Silva,&nbsp;Regina Viseu,&nbsp;Elza Tomaz","doi":"10.5415/apallergy.2022.12.e30","DOIUrl":null,"url":null,"abstract":"<p><p>Stevens-Johnson syndrome is a rare severe delayed-type hypersensitivity reaction. Even though not initially described as a side-effect of the Comirnaty® coronavirus disease 2019 (COVID-19) Vaccine, the worldwide public COVID-19 vaccination programs are uncovering this serious adverse event. We present the case of a 44-year-old woman, vaccinated with the 1st dose in July 2021, and the 2nd dose 4 weeks later. Five days after the 2nd dose, a 10 cm, circular, painful, violet/red lesion appeared on the injection site. From then on, multiple, generalized purpuric painful lesions appeared, associated with ulcers on the lips, oral cavity, nasal cavity, vulva, and vagina, oedema of the hands and feet, conjunctival erythema, blurred vision, and malaise. The patient was being treated with lamotrigine and sodium valproate (for 2 years, without interruptions or dose change) which were stopped, and the patient started treatment with systemic corticosteroids. Lymphocyte transformation test were performed and were positive for PEG2000 1 µg/mL (stimulation index [SI], 30.9), and the undiluted Comirnaty® vaccine (SI, 32.2). These tests were negative on several vaccinated controls. We can definitively show that sensitization to the vaccine and PEG2000 can occur. A more extensive evaluation and reporting is needed to know the true incidence of this life-threatening condition and possible risk factors; as not only further booster shots of this vaccine will be administered, but also new vaccines with the mRNA technology are likely to be more prevalent in the future.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 3","pages":"e30"},"PeriodicalIF":1.6000,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/34/apa-12-e30.PMC9353208.pdf","citationCount":"5","resultStr":"{\"title\":\"Stevens-Johnson syndrome related with Comirnaty® coronavirus disease 2019 vaccine.\",\"authors\":\"João Marcelino,&nbsp;João Vieira,&nbsp;Fátima Ferreira,&nbsp;Irina Didenko,&nbsp;Rute Reis,&nbsp;Rita Silva,&nbsp;Regina Viseu,&nbsp;Elza Tomaz\",\"doi\":\"10.5415/apallergy.2022.12.e30\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Stevens-Johnson syndrome is a rare severe delayed-type hypersensitivity reaction. Even though not initially described as a side-effect of the Comirnaty® coronavirus disease 2019 (COVID-19) Vaccine, the worldwide public COVID-19 vaccination programs are uncovering this serious adverse event. We present the case of a 44-year-old woman, vaccinated with the 1st dose in July 2021, and the 2nd dose 4 weeks later. Five days after the 2nd dose, a 10 cm, circular, painful, violet/red lesion appeared on the injection site. From then on, multiple, generalized purpuric painful lesions appeared, associated with ulcers on the lips, oral cavity, nasal cavity, vulva, and vagina, oedema of the hands and feet, conjunctival erythema, blurred vision, and malaise. The patient was being treated with lamotrigine and sodium valproate (for 2 years, without interruptions or dose change) which were stopped, and the patient started treatment with systemic corticosteroids. Lymphocyte transformation test were performed and were positive for PEG2000 1 µg/mL (stimulation index [SI], 30.9), and the undiluted Comirnaty® vaccine (SI, 32.2). These tests were negative on several vaccinated controls. We can definitively show that sensitization to the vaccine and PEG2000 can occur. A more extensive evaluation and reporting is needed to know the true incidence of this life-threatening condition and possible risk factors; as not only further booster shots of this vaccine will be administered, but also new vaccines with the mRNA technology are likely to be more prevalent in the future.</p>\",\"PeriodicalId\":8488,\"journal\":{\"name\":\"Asia Pacific Allergy\",\"volume\":\"12 3\",\"pages\":\"e30\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2022-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/34/apa-12-e30.PMC9353208.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia Pacific Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5415/apallergy.2022.12.e30\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.2022.12.e30","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 5

摘要

史蒂文斯-约翰逊综合征是一种罕见的严重迟发性超敏反应。尽管最初并未被描述为2019冠状病毒病(COVID-19)疫苗的副作用,但全球公共COVID-19疫苗接种计划正在发现这一严重不良事件。我们报告了一名44岁妇女的病例,她于2021年7月接种了第一剂疫苗,4周后接种了第二剂疫苗。第2次给药后5天,注射部位出现10厘米圆形、疼痛、紫色/红色病灶。此后出现多发、全身性紫癜性疼痛病变,伴唇部、口腔、鼻腔、外阴、阴道溃疡,手足水肿,结膜红斑,视力模糊,全身乏力。患者正在接受拉莫三嗪和丙戊酸钠治疗(2年,没有中断或剂量变化),并停止治疗,患者开始全身皮质类固醇治疗。进行淋巴细胞转化试验,PEG2000 1µg/mL(刺激指数[SI], 30.9)和未稀释的Comirnaty®疫苗(SI, 32.2)阳性。在几个接种过疫苗的对照组中,这些试验呈阴性。我们可以明确地表明,可以发生对疫苗和PEG2000的致敏。需要进行更广泛的评估和报告,以了解这种危及生命的疾病的真实发病率和可能的风险因素;因为不仅该疫苗的进一步加强注射将被实施,而且采用mRNA技术的新疫苗可能在未来更加普遍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Stevens-Johnson syndrome related with Comirnaty® coronavirus disease 2019 vaccine.

Stevens-Johnson syndrome related with Comirnaty® coronavirus disease 2019 vaccine.

Stevens-Johnson syndrome related with Comirnaty® coronavirus disease 2019 vaccine.

Stevens-Johnson syndrome is a rare severe delayed-type hypersensitivity reaction. Even though not initially described as a side-effect of the Comirnaty® coronavirus disease 2019 (COVID-19) Vaccine, the worldwide public COVID-19 vaccination programs are uncovering this serious adverse event. We present the case of a 44-year-old woman, vaccinated with the 1st dose in July 2021, and the 2nd dose 4 weeks later. Five days after the 2nd dose, a 10 cm, circular, painful, violet/red lesion appeared on the injection site. From then on, multiple, generalized purpuric painful lesions appeared, associated with ulcers on the lips, oral cavity, nasal cavity, vulva, and vagina, oedema of the hands and feet, conjunctival erythema, blurred vision, and malaise. The patient was being treated with lamotrigine and sodium valproate (for 2 years, without interruptions or dose change) which were stopped, and the patient started treatment with systemic corticosteroids. Lymphocyte transformation test were performed and were positive for PEG2000 1 µg/mL (stimulation index [SI], 30.9), and the undiluted Comirnaty® vaccine (SI, 32.2). These tests were negative on several vaccinated controls. We can definitively show that sensitization to the vaccine and PEG2000 can occur. A more extensive evaluation and reporting is needed to know the true incidence of this life-threatening condition and possible risk factors; as not only further booster shots of this vaccine will be administered, but also new vaccines with the mRNA technology are likely to be more prevalent in the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
5.90%
发文量
33
期刊介绍: Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信